Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

8.45USD
26 May 2017
Change (% chg)

$0.10 (+1.20%)
Prev Close
$8.35
Open
$8.35
Day's High
$8.50
Day's Low
$8.35
Volume
20,232
Avg. Vol
78,372
52-wk High
$14.60
52-wk Low
$5.50

Select another date:

Thu, May 18 2017

BRIEF-Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial

* Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting Source text for Eikon: Further company coverage:

BRIEF-Stemline Therapeutics Q1 loss per share $0.67

* Stemline therapeutics reports first quarter 2017 financial results

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

BRIEF-Stemline Therapeutics Q4 loss per share $0.56

* Stemline therapeutics reports fourth quarter 2016 financial results

BRIEF-Stemline Therapeutics provides update on pivotal BPDCN trial

* Stemline therapeutics provides update on pivotal bpdcn trial

Select another date:

More From Around the Web